☆ 4.7 Letter

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

LEUKEMIA (2008)

Journal

LEUKEMIA

Volume 22, Issue 6, Pages 1282-1284

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/sj.leu.2405100

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro

Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma

Selina Buehler, Dilara Akhoundova, Barbara Jeker, Myriam Legros, Katja Seipel, Michael Daskalakis, Ulrike Bacher, Thomas Pabst

Summary: High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for multiple myeloma (MM). This study evaluated the safety and efficacy of using ixazomib in combination with G-CSF for stem cell mobilization in MM patients. The combination showed promising mobilizing activity, although some patients required the addition of plerixafor for optimal stem cell collection.

CANCERS (2023)

Add to Collection

Article Oncology

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma

Naresh Bumma, Binod Dhakal, Raphael Fraser, Noel Estrada-Merly, Kenneth Anderson, Cesar O. Freytes, Gerhard C. Hildebrandt, Leona Holmberg, Maxwell M. Krem, Cindy Lee, Lazaros Lekakis, Hillard M. Lazarus, Hira Mian, Hemant S. Murthy, Sunita Nathan, Taiga Nishihori, Ricardo Parrondo, Sagar S. Patel, Melhem Solh, Christopher Strouse, David H. Vesole, Shaji Kumar, Muzaffar H. Qazilbash, Nina Shah, Anita D'Souza, Surbhi Sidana

Summary: This study found that bortezomib monotherapy or combination therapy did not show superior outcomes compared to lenalidomide alone as maintenance treatment in patients with high-risk multiple myeloma. Therefore, until prospective data from randomized clinical trials are available, post-transplant therapy should be individualized and consideration should be given to enrolling patients in clinical trials targeting novel therapeutic strategies for high-risk multiple myeloma. Lenalidomide should continue to be a cornerstone of treatment.

CANCER (2023)

Add to Collection

Article Medicine, General & Internal

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesus San-Miguel, Binod Dhakal, Kwee Yong, Andrew Spencer, Sebastien Anguille, Maria-Victoria Mateos, Carlos Fernandez de Larrea, Joaquin Martinez-Lopez, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, Irit Avivi, Michele Cavo, Tadao Ishida, Seok Jin Kim, Wilfried Roeloffzen, Niels W. C. J. van de Donk, Dominik Dytfeld, Surbhi Sidana, Luciano J. Costa, Albert Oriol, Rakesh Popat, Abdullah M. Khan, Yael C. Cohen, P. Joy Ho, James Griffin, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan M. Schecter, Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, T. Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele

Summary: In patients with lenalidomide-refractory multiple myeloma, Ciltacabtagene autoleucel (CAR-T cell therapy) showed a lower risk of disease progression or death compared to standard care, highlighting its effectiveness in this patient population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Hematology

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cecile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hebraud, Jill Corre, Michel Attal

Summary: The study shows that using carfilzomib, lenalidomide, and dexamethasone in combination with transplant treatment for eligible patients with newly diagnosed multiple myeloma can produce rapid and deep responses, with an acceptable safety profile. Close monitoring of cardiovascular adverse events is necessary.

BLOOD (2021)

Add to Collection

Article Oncology

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Mueller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel

Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.

LEUKEMIA (2021)

Add to Collection

Article Multidisciplinary Sciences

Nociceptive nerves regulate haematopoietic stem cell mobilization

Xin Gao, Dachuan Zhang, Chunliang Xu, Huihui Li, Kathleen M. Caron, Paul S. Frenette

Summary: Nociceptive nerves play a role in enforcing HSC mobilization through CGRP secretion, collaborating with sympathetic nerves to maintain HSCs in the bone marrow. CGRP directly activates HSCs via the G alpha(s)/adenylyl cyclase/cAMP pathway, and consumption of capsaicin-containing food enhances HSC mobilization in mice.

NATURE (2021)

Add to Collection

Article Hematology

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Laura Rosinol, Albert Oriol, Rafael Rios, Maria Jesus Blanchard, Isidro Jarque, Joan Bargay, Miguel Teodoro Hernandez, Valentin Cabanas, Estrella Carrillo-Cruz, Anna Sureda, Joaquin Martinez-Lopez, Isabel Krsnik, Maria Esther Gonzalez, Luis Felipe Casado, Josep Maria Marti, Cristina Encinas, Felipe de Arriba, Luis Palomera, Antonia Sampol, Yolanda Gonzalez-Montes, Elena Cabezudo, Bruno Paiva, Noemi Puig, Maria Teresa Cedena, Javier de la Cruz, Maria-Victoria Mateos, Jesus San Miguel, Juan Jose Lahuerta, Joan Blade

Summary: This study compared the efficacy of maintenance therapy with RD and IRD in patients with multiple myeloma. The results showed that RD maintenance therapy was effective and discontinuation of maintenance therapy in patients with negative MRD at 2 years was safe.

BLOOD (2023)

Add to Collection

Article Oncology

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)

Matthew Ho, Saurabh Zanwar, Prashant Kapoor, Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, David Dingli, Francis Baudi, Eli Muchtar, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Amie Fonder, Lisa Hwa, Miriam Hobbs, Robert Kyle, S. Vincent Rajkumar, Shaji Kumar

Summary: This study suggests that MM patients receiving >= 3 years of lenalidomide maintenance post-ASCT have superior outcomes. Lenalidomide refractoriness at first relapse is associated with inferior survival. At first relapse post-maintenance, daratumumab-based regimens show better survival outcomes.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Hematology

Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma

Peter Barth, Smith Giri, John L. Reagan, Adam J. Olszewski

Summary: The triplet regimen of lenalidomide, bortezomib, and dexamethasone (RVD) demonstrated better survival and event-free survival compared to doublet regimens RD or VD. Out of the doublet regimens, RD showed better event-free survival but had higher risk of thromboembolic events compared to VD. VCD did not show significant differences compared to VD in any outcome.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander

Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

High Efficacy of Stem Cell Mobilization With Etoposide plus Cytarabine Plus G-CSF in Patients With Multiple Myeloma

Zhijuan Zhu, Xiaofan Li, Yiping Liu, Ping Chen, Xianling Chen, Hua Li, Jiafu Huang, Yuanzhong Chen, Nainong Li

Summary: Efficient and safe mobilization of CD34+ hematopoietic stem cells was achieved in patients with MM using Etoposide + Cytarabine plus G-CSF, which could be considered for high-risk MM patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Hematology

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

Georgia J. McCaughan, Sara Gandolfi, John J. Moore, Paul G. Richardson

Summary: For patients with newly diagnosed multiple myeloma, optimizing induction therapy is crucial for long-term disease control. The current standard of care involves the combination of lenalidomide and bortezomib with dexamethasone (RVD) as induction treatment, followed by maintenance until disease progression.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Elias K. Mai, Kaya Miah, Uta Bertsch, Jan Duerig, Christof Scheid, Katja C. Weisel, Christina Kunz, Markus Munder, Hans-Walter Lindemann, Maximilian Merz, Dirk Hose, Anna Jauch, Anja Seckinger, Steffen Luntz, Sandra Sauer, Stephan Fuhrmann, Peter Brossart, Ahmet Elmaagacli, Martin Goerner, Helga Bernhard, Martin Hoffmann, Marc S. Raab, Igor W. Blau, Mathias Haenel, Axel Benner, Hans J. Salwender, Hartmut Goldschmidt

Summary: Intensive upfront therapy for newly-diagnosed multiple myeloma patients up to age 70 is feasible, with similar treatment adherence across age groups but increased overall toxicity in older patients. Age does not impact progression-free or overall survival outcomes in this setting.

LEUKEMIA (2021)

Add to Collection

Article Oncology

An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission

Luca Biavati, Carol Ann Huff, Anna Ferguson, Amy Sidorski, M. Amanda Stevens, Lakshmi Rudraraju, Cristina Zucchinetti, Syed Abbas Ali, Philip Imus, Christian B. Gocke, Rachel M. Gittelman, Sarah Johnson, Catherine Sanders, Marissa Vignali, Anita Gandhi, Xiaobu Ye, Kimberly A. Noonan, Ivan Borrello

Summary: This proof-of-principle clinical trial showed that the combination of GM-CSF-secreting vaccine and lenalidomide could deepen the clinical response in multiple myeloma patients in sustained near complete remission. The treatment effectively primed durable immunity, resulting in long-term disease control and prolonged clinical responses for patients in a nCR status, with measurable cytokine responses persisting up to 7 years.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Hematology

Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice

Zhi Wen, Adhithi Rajagopalan, Evan D. Flietner, Grant Yun, Marta Chesi, Quinlan Furumo, Robert T. Burns, Athanasios Papadas, Erik A. Ranheim, Adam C. Pagenkopf, Zachary T. Morrow, Remington Finn, Yun Zhou, Shuyi Li, Xiaona You, Jeffrey Jensen, Mei Yu, Alexander Cicala, James Menting, Constantine S. Mitsiades, Natalie S. Callander, P. Leif Bergsagel, Demin Wang, Fotis Asimakopoulos, Jing Zhang

Summary: NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma, with poor patient outcomes. A novel MM model was generated in mice, exhibiting characteristics similar to human advanced/high-risk MM. MEK inhibition-based therapies significantly prolonged survival in advanced-stage MM mice, suggesting potential for future clinical application.

BLOOD (2021)

Add to Collection

Article Cell Biology

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Zongwei Li, Huan Liu, Jin He, Zhiqiang Wang, Zheng Yin, Gichun You, Zhiming Wang, Richard E. Davis, Pei Lin, Leif Bergsagel, Elisabet E. Manasanch, Stephen T. C. Wong, Nestor F. Esnaola, Jenny C. Chang, Robert Z. Orlowski, Qing Yi, Jing Yang

Summary: The study indicates that acetyl-CoA synthetase 2 (ACSS2) plays an important role in obesity-related myeloma progression, interacting with oncoprotein interferon regulatory factor 4 (IRF4) to enhance tumor growth. Overexpression of ACSS2 contributes to IRF4 stability and gene transcription, reducing myeloma growth in an obese mouse model.

CELL METABOLISM (2021)

Add to Collection

Article Oncology

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

Yan W. Asmann, Kaushal Parikh, P. Leif Bergsagel, Haidong Dong, Alex A. Adjei, Mitesh J. Borad, Aaron S. Mansfield

Summary: The recent FDA approval of TMB-H status as a biomarker for PD-1 inhibitor treatment highlights the importance of accurate assessment of patient-specific TMB. Research shows that using public databases for TMB estimation without patient-paired germline sequencing may introduce racial bias, with TMB being more inflated in Black patients compared to White patients.

NPJ PRECISION ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update

Eli Muchtar, Angela Dispenzieri, Morie A. Gertz, Shaji K. Kumar, Francis K. Buadi, Nelson Leung, Martha Q. Lacy, David Dingli, Sikander Ailawadhi, P. Leif Bergsagel, Rafael Fonseca, Suzanne R. Hayman, Prashant Kapoor, Martha Grogan, Omar F. Abou Ezzeddine, Julie L. Rosenthal, Michelle Mauermann, Mustaqueem Siddiqui, Wilson Gonsalves, Taxiarchis Kourelis, Jeremy T. Larsen, Craig B. Reeder, Rahma Warsame, Ronald S. Go, David L. Murray, Ellen D. McPhail, Surendra Dasari, Dragan Jevremovic, Robert A. Kyle, Yi Lin, John A. Lust, Stephen J. Russell, Yi Lisa Hwa, Amie L. Fonder, Miriam A. Hobbs, S. Vincent Rajkumar, Vivek Roy, Taimur Sher

Summary: AL amyloidosis is a clonal plasma cell disorder that can lead to organ failure. Early recognition, anti-plasma cell therapy, and supportive care are important for improving patient survival.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Oncology

Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care

Sandeep S. Voleti, Rahma Warsame, Carolyn Mead-Harvey, Sikander Ailawadhi, Atul Jain, Rafael Fonseca, Joan M. Griffin, Nandita Khera

Summary: This study presents a standardized approach to describe the prevalence and predictors of financial hardship (FH) in cancer patients and examines its association with survival. It highlights the need for further research to develop care pathways for patients at high risk of poor financial and clinical outcomes.

JCO ONCOLOGY PRACTICE (2022)

Add to Collection

Review Oncology

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Rafael Fonseca, Diana Tran, Alyshia Laidlaw, Emily Rosta, Manvir Rai, Joana Duran, Eric M. Ammann

Summary: This systematic literature review aimed to understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life in multiple myeloma patients. Through multiple rounds of screening, 41 studies were included, indicating that disease progression and increasing lines of therapy were associated with worsened patient HRQoL, while increasing depth of response was associated with improved patient HRQoL.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Article Oncology

Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy

Erin W. Meermeier, Seth J. Welsh, Meaghen E. Sharik, Megan T. Du, Victoria M. Garbitt, Daniel L. Riggs, Chang-Xin Shi, Caleb K. Stein, Marco Bergsagel, Bryant Chau, Matthew L. Wheeler, Natalie Bezman, Feng Wang, Pavel Strop, P. Leif Bergsagel, Marta Chesi

Summary: A study on BCMA/CD3-targeting bispecific antibodies (BsAb) in mouse models of multiple myeloma revealed that the BsAb was safe and effective in some cases but not in those with high tumor burden, with combination with pomalidomide showing improved efficacy but limited survival due to toxicity and T-cell exhaustion. However, combining with cyclophosphamide was safe and prevented T-cell exhaustion, promoting long-term disease control.

BLOOD CANCER DISCOVERY (2021)

Add to Collection

Review Oncology

Chromosome 1q21 abnormalities in multiple myeloma

Timothy M. Schmidt, Rafael Fonseca, Saad Z. Usmani

Summary: +1q chromosome gain is common in multiple myeloma, often seen as a poor prognostic marker but not uniformly adopted as high-risk. Controversy exists regarding its importance, with many genes at the 1q21 locus proposed to cause resistance to therapy.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea

Summary: The impact of disease progression on healthcare resource utilization and costs among multiple myeloma patients who have undergone stem cell transplant and systemic anti-myeloma therapy is significant.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Oncology

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Philippe Moreau, Shaji K. Kumar, Jesus San Miguel, Faith Davies, Elena Zamagni, Nizar Bahlis, Heinz Ludwig, Joseph Mikhael, Evangelos Terpos, Fredrik Schjesvold, Thomas Martin, Kwee Yong, Brian G. M. Durie, Thierry Facon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels van de Donk, Sagar Lonial, Michele Cavo, Sigurdur Y. Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C. Anderson, Cristina Joao, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G. Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Blade, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf-Henrik Mellqvist, Dominik Dytfeld, Jean-Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksac, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria-Victoria Mateos, S. Vincent Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson

Summary: This policy review presents clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma, integrating drug access issues for patients in different income settings to improve patient outcomes in real-world practice.

LANCET ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.

Nadine Abdallah, Francis Buadi, Patricia T. Greipp, Morie A. Gertz, Prashant Kapoor, Angela Dispenzieri, Linda Baughn, Martha Lacy, Suzanne R. Hayman, David Dingli, Ronald S. Go, Miriam A. Hobbs, Yi Lin, Taxiarchis Kourelis, Mustaqeem Ahmad Siddiqui, Robert A. Kyle, Rhett P. Ketterling, S. Vincent Rajkumar, Leif P. Bergsagel, Shaji Kumar

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Anti-BCMA bispecific tool therapy against Vk*MYC multiple myeloma is enhanced by IMiDs

Erin W. Meermeier, Meaghen E. Sharik, Seth J. Welsh, Caleb K. Stein, Victoria M. Garbitt, Sochilt Brown, Kennedi T. Todd, Marco Bergsagel, P. Leif Bergsagel, Marta Chesi

CANCER RESEARCH (2020)

Add to Collection

Meeting Abstract Oncology

scRNA-seq reveals restructuring of the immune microenvironment of multiple myeloma following treatment with an IAP antagonist

Caleb K. Stein, Erin Meermeier, Seth Welsh, Victoria Garbitt, Meaghen Sharik, P. Leif Bergsagel, Nicholas Banovich, Jonathan Keats, Marta Chesi

CANCER RESEARCH (2020)

Add to Collection

Meeting Abstract Hematology

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis

Eli Muchtar, Morie A. Gertz, Betsy Laplant, Francis K. Buadi, Nelson Leung, Stephanie M. Peterson, P. Leif Bergsagel, Amie Fonder, Yi L. Hwa, Miriam A. Hobbs, Dania Kaehlyn Helgeson, Alanna M. Vossen, Wilson I. Gonsalves, Martha Q. Lacy, Prashant Kapoor, Mustaqeem A. Siddiqui, Jeremy Larsen, Rahma M. Warsame, Suzanne R. Hayman, Ronald S. Go, David Dingli, Taxiarchis Kourelis, Angela Dispenzieri, S. Vincent Rajkumar Md, Shaji K. Kumar

BLOOD (2020)

Add to Collection

Meeting Abstract Hematology

Heterogeneity of MYC Abnormalities in Multiple Myeloma

Neeraj Sharma, James B. Smadbeck, Nadine Abdallah, Kathryn E. Pearce, Yan Asmann, Jess Peterson, Rhett P. Ketterling, Patricia Greipp, P. Leif Bergsagel, S. Vincent Rajkumar, Shaji K. Kumar, Linda B. Baughn

BLOOD (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.